Denmark· DK-28106644921
Blomensy
A rivaroxaban product containing rivaroxaban, registered in Denmark by Egis Pharmaceuticals PLC. The same ATC class is registered in 15 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Rivaroxaban is registered in 15 of 19 countries.
Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Rivaroxaban · ATC B01AF01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rivaroxaban costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rivaroxaban · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- US United States$5.20 (acquisition cost)
- CH Switzerland$2.66
- IT Italy$1.08
- FR France$0.67
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Rivaroxaban
- Manufacturer
- Egis Pharmaceuticals PLC
- Country
- Denmark (DK)
- ATC code
- B01AF01
- ATC class
- Rivaroxaban
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106644921
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
391 interactions on record for rivaroxaban.
Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rivaroxaban · interactions on record
391 records
- 134 severe
- 213 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
42 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B01AF01
Rivaroxaban, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eaf8a3b6-9f30-4cf5-906c-c2888e63131e GET /v1/drugs/eaf8a3b6-9f30-4cf5-906c-c2888e63131e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "15 mg",
"auth_role": "CMS",
"dk_drugid": "28106644921",
"substance": "Rivaroxaban",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": false,
"registration_date_serial": "44903"
}See everything about rivaroxaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.